Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
Assistant Member, St. Jude Faculty
Director, Bone Marrow Transplant Fellowship Program
Bone Marrow Transplantation & Cellular Therapy
David Shook, MD
Bone Marrow Transplantation & Cellular Therapy
MS 1130, Room I-3307
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: david.shook@stjude.org
Phone: (901) 595-2369
FAX: (901) 595-7944
BS - Purdue University, West Lafayette, Indiana
MD - Johns Hopkins University School of Medicine, Baltimore, Maryland
Shook DR, Leung W. Natural killer cell therapy for cancer: delivering on a promise. Transfusion 53(2):245-8, 2013.
Shook DR, Triplett BM, Srinivasan A, Hartford C, Dallas MH, Pillai A, Laver J, Leung W. Successful allogeneic hematopoietic cell engraftment following a minimal conditioning regimen in children with relapsed or refractory solid tumors. Biol Blood Marrow Transplant October 9, 2012.
Inaba H, Yang J, Kaste SC, Hartford CM, Motosue MS, Chemaitilly W, Triplett BM, Shook DR, Pui CH, Leung W. Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol October 1, 2012.
Triplett BM, Wang C, Yang J, Dallas M, Hartford C, Howard V, Pillai A, Shook D, Srinivasan A, Laver J, Leung W. Effects of conditioning regimens and T-cell depletion in hematopoietic cell transplantation for primary immune deficiency. Biol Blood Marrow Transplant July 26, 2012.
Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood April 19, 2012.
Shook DR, Campana D. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78(6):409-415, 2011.
Cho D*, Shook DR*, Shimasaki N, Chang YS, Fujisaki H, Campana D. Natural killer cell activity against pediatric solid tumors. Clin Cancer Res 16(15):3901-3909, 2010.
Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE, Campana D. Minimal residual disease quantitation in acute myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia 9(Suppl 3):S281-285, 2009.
Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Recurrent micropapillary serous ovarian carcinoma: The role of secondary cytoreductive surgery. Cancer 95(4):792-800, 2002.
Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 86(2):163-170, 2002.
Last update: February 2013
